Immunome gains 28% pre-market as varegacestat trial meets primary endpoint

lunes, 15 de diciembre de 2025, 7:05 am ET1 min de lectura
IMNM--

Immunome gains 28% pre-market as varegacestat trial meets primary endpoint

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios